Molecular Genetic Factors of Risk Stratification of Lymph Node Metastasis in Endometrial Carcinoma
Open Access
Abstract
Background: According to epidemiological studies, endometrial carcinoma is one of the most frequently diagnosed malignancies of the female reproductive system, with an increasing incidence. Currently, the risk stratification of this neoplasm takes into account the stage, degree of tumor differentiation, histological type and depth of myometrial invasion. Since the publication of the last International Federation of Gynecology and Obstetrics (FIGO) staging system for endometrial cancer in 2009, numerous reports have appeared on the molecular characteristics of different types of endometrial carcinoma. Taking this into account, the FIGO Committee determined in 2023 that changes and updates to the staging system are justified to reflect new information about this tumor. Due to the high prevalence of the disease and mortality from endometrial cancer, an in-depth study of the molecular genetic characteristics of tumor cells is relevant; the results of such studies can be used to improve the efficiency of diagnosis, assess the risk of metastasis and prognosis of the disease. Lymph node assessment is crucial for the choice of treatment strategy for endometrial cancer, since metastatic lymph node involvement is one of the main factors affecting prognosis. At the same time, the criteria for the appropriateness of lymphadenectomy in low-differentiated malignant tumors are not clearly defined. Various molecular methods have been proposed to assess the status of lymph nodes; candidate genes are being studied as potential diagnostic biomarkers, as well as microRNA. The aim of the study was to analyze the literature data on numerous studies of molecular risk factors for progression in endometrioid carcinoma, as well as to preserve the most important marker changes in relation to the prognostic development of this disease. Methods: A literature review was conducted using data from the electronic databases PubMed, Google Scholar, and Wiley Cochrane Library for the period from 2018 to 2023 using the specific keywords. Results: The current scientific genetic studies on metastasis and prognostic factors in uterine cancer were analyzed, and a systematization of the reviewed data from the modern literature was done. Conclusions: To select the most effective treatment - intraoperative, adjuvant or combination therapy, minimize postoperative risks of lymphadenectomy and clearly predict the results - further study of the molecular genetic features of endometrial cancer is necessary.Keywords
This publication has 58 references indexed in Scilit:
- TMEFF2 is a novel prognosis signature and target for endometrial carcinomaLife Sciences, 2020
- MicroRNA-135a promotes proliferation, migration, invasion and induces chemoresistance of endometrial cancer cellsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology: X, 2020
- Discovery and validation of candidate host DNA methylation markers for detection of cervical precancer and cancerInternational Journal of Cancer, 2017
- The molecular basis of breast cancer pathological phenotypesThe Journal of Pathology, 2016
- Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer – A pooled analysis of PORTEC 1 and 2 trialsEuropean Journal of Cancer, 2015
- Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinomaClinical and Translational Oncology, 2015
- Therapeutic role of lymph node resection in endometrioid corpus cancerCancer, 2006
- Identification and Characterization of TMEFF2, a Novel Survival Factor for Hippocampal and Mesencephalic NeuronsGenomics, 2000
- Surgical pathologic spread patterns of endometrial cancer: A gynecologic oncology group studyCancer, 1987
- Two pathogenetic types of endometrial carcinomaGynecologic Oncology, 1983